Autolus Therapeutics plc (NASDAQ:AUTL) Receives Average Rating of “Buy” from Analysts

Autolus Therapeutics plc (NASDAQ:AUTL) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $9.52.

A number of research analysts have issued reports on AUTL shares. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday, March 21st.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently modified their holdings of AUTL. Jane Street Group LLC acquired a new position in Autolus Therapeutics during the fourth quarter valued at approximately $26,000. Barclays PLC boosted its position in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after purchasing an additional 10,866 shares during the period. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the 3rd quarter valued at $51,000. Dumont & Blake Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics during the fourth quarter worth about $35,000. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 5.3 %

NASDAQ:AUTL opened at $1.62 on Friday. Autolus Therapeutics has a twelve month low of $1.56 and a twelve month high of $6.48. The company has a market capitalization of $431.07 million, a P/E ratio of -1.34 and a beta of 2.07. The firm has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $2.87.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million. On average, equities research analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.